Health ❯ Healthcare

Biotechnology

Drug Development Clinical Trials Gene Therapy Cancer Treatment Gene Editing Pharmaceuticals Therapeutics Immunotherapy Clinical Research Vaccine Development

Kailera Prices Upsized $625 Million IPO at $16 a Share

The deal funds late-stage work on ribupatide to compete with leading obesity drugs.

Stories older than 24h

FDA Grants Orphan Drug Status to Immutep’s Efti for Soft Tissue Sarcoma

Transgene Completes Phase 2 Randomization for Personalized Cancer Vaccine TG4050

Jeito Capital Closes $1.2 Billion Second Fund in Claimed European Biopharma Record

CRISPR Therapeutics’ Pipeline Pitched as Path to One-Time Heart Risk Treatments

ImmunityBio Faces Growing Securities Suits After FDA Flags Misleading Anktiva Claims

SCYNEXIS Acquires Poxel’s PXL-770 for ADPKD, Plans 2026 Phase 2 Trial

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

Investor Class Actions Target Atara Over FDA Setbacks to EBVALLO

FDA Grants Accelerated Approval to Kresladi, First Gene Therapy for Severe Pediatric LAD-1

ImmunityBio Sued in Securities Class Action Over Anktiva Marketing Claims

DBV Technologies Files 2025 Annual Report, Extends Runway as 2026 Peanut Patch Filings Near

Sarepta Reports Early siRNA Data Showing Muscle Delivery as Shares Surge

Wave Life Sciences Shares Plunge 30% After Early Obesity Trial Readout

FDA Grants Accelerated Approval to Avlayah for Neurologic Manifestations of Hunter Syndrome

Sanofi Licenses Kali’s Tri-Specific Autoimmune Antibody KT501 in Deal Worth Up to $1.23 Billion

Plaintiff Firms Intensify Biotech Securities Suits as Key Deadlines Near for Nektar, uniQure and REGENXBIO

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Apogee to Report 52-Week Phase 2 Data for Zumilokibart in Atopic Dermatitis Today

RTW Buys $116 Million of Cogent Biosciences as Kynam Trims $48 Million Stake